Breakthrough Therapy Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
ACHL | F | Achilles Therapeutics plc | -1.78 | |
TSVT | F | 2seventy bio, Inc. | -8.30 | |
PPBT | F | Purple Biotech Ltd. | 6.15 |
Related Industries: Biotechnology Long-Term Care Facilities Medical Care Facilities
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
CNCR | D | Loncar Cancer Immunotherapy ETF | 1.79 | |
WDNA | D | WisdomTree BioRevolution Fund | 0.9 | |
GNOM | D | Global X Genomics & Biotechnology ETF | 0.43 | |
BTEC | C | Principal Healthcare Innovators Index ETF | 0.09 | |
IWC | C | iShares Microcap ETF | 0.06 |
Compare ETFs
- Breakthrough Therapy
Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act. The FDA's "breakthrough therapy" designation is not intended to imply that a drug is actually a "breakthrough" or that there is high-quality evidence of treatment efficacy for a particular condition; rather, it allows the FDA to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases. The FDA has other mechanisms for expediting the review and approval process for promising drugs, including fast track designation, accelerated approval, and priority review.
Recent Comments
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
- TraderMike on Market Recap for Friday, March 8, 2024
- Don_Marat on Market Recap for Friday, March 8, 2024
From the Blog
Featured Articles